Delivery of doxorubicin-loaded PLGA nanoparticles into U87 human glioblastoma cells

Malinovskaya, Julia; Melnikov, Pavel; Baklaushev, V. P.; Габашвили, А. Н.; Osipova, Nadezhda; Mantrov, S. N.; Ermolenko, Yulia; Maksimenko, Olga; Gorshkova, M. Yu.; Balabanyan, Vadim; Kreuter, Jörg; Gelperina, Svetlana

doi:10.1016/j.ijpharm.2017.03.049

Cited by 138 publications

(94 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Manlioovskaya et al demonstrated that these same nanoparticles entered U87 human GBM cells via clathrin-mediated endocytosis. They also demonstrated that the nanoparticles released their doxorubicin via diffusion rather than by intracellular degradation [175]. These studies prove that PLGA nanoparticles coated with poloxamer 188 could improve the delivery of doxorubicin and potentially other chemotherapeutic drugs into brain tumours.…”

Section: Targeted Polymeric Nanoparticles For the Treatment Of Malignmentioning

confidence: 83%

Polymeric Nanoparticles for the Treatment of Malignant Gliomas

Mahmoud

Alamri

McConville

2020

Cancers

View full text Add to dashboard Cite

Malignant gliomas are one of the deadliest forms of brain cancer and despite advancements in treatment, patient prognosis remains poor, with an average survival of 15 months. Treatment using conventional chemotherapy does not deliver the required drug dose to the tumour site, owing to insufficient blood brain barrier (BBB) penetration, especially by hydrophilic drugs. Additionally, low molecular weight drugs cannot achieve specific accumulation in cancerous tissues and are characterized by a short circulation half-life. Nanoparticles can be designed to cross the BBB and deliver their drugs within the brain, thus improving their effectiveness for treatment when compared to administration of the free drug. The efficacy of nanoparticles can be enhanced by surface PEGylation to allow more specificity towards tumour receptors. This review will provide an overview of the different therapeutic strategies for the treatment of malignant gliomas, risk factors entailing them as well as the latest developments for brain drug delivery. It will also address the potential of polymeric nanoparticles in the treatment of malignant gliomas, including the importance of their coating and functionalization on their ability to cross the BBB and the chemistry underlying that.

show abstract

Section: Targeted Polymeric Nanoparticles For the Treatment Of Malignmentioning

confidence: 83%

Polymeric Nanoparticles for the Treatment of Malignant Gliomas

Mahmoud

Alamri

McConville

2020

Cancers

View full text Add to dashboard Cite

show abstract

“…In addition, we found that EMAP-II combined with anti-miR-330-3p and PKC-α activator could enhance the effects of DOX on inhibiting the cell viability and promoting apoptosis of glioma cells. DOX exhibited a high anti-tumor effect against the glioblastoma, inhibited the growth of U87 glioma cells and was used to evaluate the anti-glioma effects of various drugs across the BTB (Zheng et al, 2015 ; Chen et al, 2017 ; Malinovskaya et al, 2017 ). Therefore, our study revealed that the combination of EMAP-II with other anti-glioma drugs may be a new way of comprehensive treatment of glioma.…”

Section: Discussionmentioning

confidence: 99%

The Role of miR-330-3p/PKC-α Signaling Pathway in Low-Dose Endothelial-Monocyte Activating Polypeptide-II Increasing the Permeability of Blood-Tumor Barrier

Liu

Chao

et al. 2017

Front. Cell. Neurosci.

View full text Add to dashboard Cite

This study was performed to determine whether EMAP II increases the permeability of the blood-tumor barrier (BTB) by affecting the expression of miR-330-3p as well as its possible mechanisms. We determined the over-expression of miR-330-3p in glioma microvascular endothelial cells (GECs) by Real-time PCR. Endothelial monocyte-activating polypeptide-II (EMAP-II) significantly decreased the expression of miR-330-3p in GECs. Pre-miR-330-3p markedly decreased the permeability of BTB and increased the expression of tight junction (TJ) related proteins ZO-1, occludin and claudin-5, however, anti-miR-330-3p had the opposite effects. Anti-miR-330-3p could enhance the effect of EMAP-II on increasing the permeability of BTB, however, pre-miR-330-3p partly reversed the effect of EMAP-II on that. Similarly, anti-miR-330-3p improved the effects of EMAP-II on increasing the expression levels of PKC-α and p-PKC-α in GECs and pre-miR-330-3p partly reversed the effects. MiR-330-3p could target bind to the 3′UTR of PKC-α. The results of in vivo experiments were similar to those of in vitro experiments. These suggested that EMAP-II could increase the permeability of BTB through inhibiting miR-330-3p which target negative regulation of PKC-α. Pre-miR-330-3p and PKC-α inhibitor decreased the BTB permeability and up-regulated the expression levels of ZO-1, occludin and claudin-5 while anti-miR-330-3p and PKC-α activator brought the reverse effects. Compared with EMAP-II, anti-miR-330-3p and PKC-α activator alone, the combination of the three combinations significantly increased the BTB permeability. EMAP-II combined with anti-miR-330-3p and PKCα activator could enhance the DOX’s effects on inhibiting the cell viabilities and increasing the apoptosis of U87 glioma cells. Our studies suggest that low-dose EMAP-II up-regulates the expression of PKC-α and increases the activity of PKC-α by inhibiting the expression of miR-330-3p, reduces the expression of ZO-1, occludin and claudin-5, and thereby increasing the permeability of BTB. The results can provide a new strategy for the comprehensive treatment of glioma.

show abstract

“…The imaging agents can be encapsulated into PLGA-based DDSs or conjugated on to the outer surface of PLGA-based DDSs through the covalently linking with functional groups (such as carboxylic acid and hydroxyl groups) of PLGA (Martins et al, 2018). For example, the imaging agents which possess the amine groups can be covalently linked to the terminal carboxylic acid groups of PLGA by forming an amide linkage (Malinovskaya et al, 2017). Additionally, the imaging agents can also be introduced into PLGA by an appropriate linker such bifunctional PEG linker (El-Gogary et al, 2014;Park et al, 2014).…”

Section: Design Of Plga-based Ddss With Imaging Propertymentioning

confidence: 99%

PLGA-Based Drug Delivery Systems for Remotely Triggered Cancer Therapeutic and Diagnostic Applications

Shen

Xie

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Intelligent drug delivery systems based on nanotechnology have been widely developed and investigated in the field of nanomedicine since they were able to maximize the therapeutic efficacy and minimize the undesirable adverse effects. Among a variety of organic or inorganic nanomaterials available to fabricate drug delivery systems (DDSs) for cancer therapy and diagnosis, poly(D,L-lactic-co-glycolic acid) (PLGA) has been extensively employed due to its biocompatibility and biodegradability. In this paper, we review the recent status of research on the application of PLGAbased drug delivery systems (DDSs) in remotely triggered cancer therapy and the strategies for tumor imaging provided by PLGA-based DDSs. We firstly discuss the employment of PLGA-based DDSs for remotely triggered cancer therapy, including photo-triggered, ultrasound-triggered, magnetic field-triggered, and radiofrequencytriggered cancer therapy. Photo-triggered cancer therapy involves photodynamic therapy (PDT), photothermal therapy (PTT), and photo-triggered chemotherapeutics release. Ultrasound-triggered cancer therapy involves high intensity focused ultrasound (HIFU) treatment, ultrasound-triggered chemotherapeutics release, and ultrasoundenhanced efficiency of gene transfection. The strategies which endows PLGA-based DDSs with imaging properties and the PLGA-based cancer theranostics are further discussed. Additionally, we also discuss the targeting strategies which provide PLGAbased DDSs with passive, active or magnetic tumor-targeting abilities. Numerous studies cited in our review demonstrate the great potential of PLGA-based DDSs as effective theranostic agent for cancer therapy and diagnosis.

show abstract

Delivery of doxorubicin-loaded PLGA nanoparticles into U87 human glioblastoma cells

Cited by 138 publications

References 45 publications

Polymeric Nanoparticles for the Treatment of Malignant Gliomas

Polymeric Nanoparticles for the Treatment of Malignant Gliomas

The Role of miR-330-3p/PKC-α Signaling Pathway in Low-Dose Endothelial-Monocyte Activating Polypeptide-II Increasing the Permeability of Blood-Tumor Barrier

PLGA-Based Drug Delivery Systems for Remotely Triggered Cancer Therapeutic and Diagnostic Applications

Contact Info

Product

Resources

About